GTBP

GT Biopharma Inc. (GTBP) is an innovative clinical-stage biopharmaceutical company based in Beverly Hills, California, dedicated to advancing immuno-oncology treatments through its proprietary Tri-specific Killer Engager (TriKE) technology. This cutting-edge platform is designed to enhance the immune system's ability to target and destroy cancer cells, positioning GT Biopharma at the forefront of one of the most dynamic sectors in oncology. With a strong pipeline of candidates aimed at addressing significant unmet medical needs, the company is well-equipped to impact treatment paradigms and improve patient outcomes in the fight against cancer. As it progresses through clinical trials, GT Biopharma demonstrates substantial promise for revolutionizing cancer therapy.